Cargando…

HFE hemochromatosis: an overview about therapeutic recommendations

Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cancado, Rodolfo D., Alvarenga, Aline Morgan, Santos, Paulo Caleb JL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885398/
https://www.ncbi.nlm.nih.gov/pubmed/34824033
http://dx.doi.org/10.1016/j.htct.2021.06.020
_version_ 1784660410215956480
author Cancado, Rodolfo D.
Alvarenga, Aline Morgan
Santos, Paulo Caleb JL
author_facet Cancado, Rodolfo D.
Alvarenga, Aline Morgan
Santos, Paulo Caleb JL
author_sort Cancado, Rodolfo D.
collection PubMed
description Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other iron overload diseases or conditions which can lead to this phenotype. In the present review, the main aims are to show updates on hemochromatosis and to report a practical set of therapeutic recommendations for the human factors engineering protein (HFE) hemochromatosis for the p.Cys282Tyr (C282Y/C282Y) homozygous genotype, elaborated by the Haemochromatosis International Taskforce.
format Online
Article
Text
id pubmed-8885398
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedade Brasileira de Hematologia e Hemoterapia
record_format MEDLINE/PubMed
spelling pubmed-88853982022-03-04 HFE hemochromatosis: an overview about therapeutic recommendations Cancado, Rodolfo D. Alvarenga, Aline Morgan Santos, Paulo Caleb JL Hematol Transfus Cell Ther Special Article Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other iron overload diseases or conditions which can lead to this phenotype. In the present review, the main aims are to show updates on hemochromatosis and to report a practical set of therapeutic recommendations for the human factors engineering protein (HFE) hemochromatosis for the p.Cys282Tyr (C282Y/C282Y) homozygous genotype, elaborated by the Haemochromatosis International Taskforce. Sociedade Brasileira de Hematologia e Hemoterapia 2022 2021-11-17 /pmc/articles/PMC8885398/ /pubmed/34824033 http://dx.doi.org/10.1016/j.htct.2021.06.020 Text en © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Special Article
Cancado, Rodolfo D.
Alvarenga, Aline Morgan
Santos, Paulo Caleb JL
HFE hemochromatosis: an overview about therapeutic recommendations
title HFE hemochromatosis: an overview about therapeutic recommendations
title_full HFE hemochromatosis: an overview about therapeutic recommendations
title_fullStr HFE hemochromatosis: an overview about therapeutic recommendations
title_full_unstemmed HFE hemochromatosis: an overview about therapeutic recommendations
title_short HFE hemochromatosis: an overview about therapeutic recommendations
title_sort hfe hemochromatosis: an overview about therapeutic recommendations
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885398/
https://www.ncbi.nlm.nih.gov/pubmed/34824033
http://dx.doi.org/10.1016/j.htct.2021.06.020
work_keys_str_mv AT cancadorodolfod hfehemochromatosisanoverviewabouttherapeuticrecommendations
AT alvarengaalinemorgan hfehemochromatosisanoverviewabouttherapeuticrecommendations
AT santospaulocalebjl hfehemochromatosisanoverviewabouttherapeuticrecommendations